DOCSLIB.ORG

Ligand P-Gp Inhibition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ligand P-Gp Inhibition ligand P-gp inhibition (11-Me-Leu)-Cyclosporin A 1 1,2,3,4-Tetrahydro-1-methyl-6,7-isoquinolinediol 0 1,2,3,4-Tetrahydro-6,7-dimethoxy-isoquinoline 0 1,2,3,4-Tetrahydro-isoquinoline 0 1,3,5-Triazacycloheptane 4b 1 1,3,5-Triazacycloheptane 4c 1 1,3,5-Triazacycloheptane 5b 1 1,3,5-Triazacycloheptane 5c 1 1,3,5-Triazacycloheptane 5d 1 1,3,5-Triazacycloheptane 6b 1 1,3,5-Triazacycloheptane 6c 1 1-(3-methoxyphenyl)-N,N-dimethylmethanamine 0 1-(4-chlorbenzhydryl)piperazine 0 1-Benzyl-3-pyrroline 0 1-Benzylimidazole 0 1-Phenethylpiperidine 0 1-Phenylpiperazine 0 11-Deoxycortisol 1 14-Benzoylyohimbine 1 16-Dehydroprogesterone 1 16-Methylprogesterone 1 17-Hydroxypregnenolone 0 17-Hydroxyprogesterone 1 2,2'-Diphenylethylamine 0 2,4,6,8-Tetradiethano 0 2,4,6,8-Tetramopholin 0 2,4,6,8-Tetrapiperidy 0 2,4,6-Trimorpholinepy 0 2,4,8-Trimorpholinepy 0 2-Benzylpyridine 0 2-Chloro-10-[2-(dimethylamino)ethyl] phenothiazine 1 2-Chloro-10-[4-(dimethylamino)butyl] phenothiazine 1 2-Chloroimipramine 1 2-Oxazolidinone 0 3'-4'-Dichlorobenzamil 0 3,8-Dihydroxychlorpromazine 0 3-Methyl choroquine 1 4,8-Dipiperidyl-2,6-D 0 4,8-Dipiperidyl-2,6-M 0 4,8-Dipiperidyl-Dimet 0 4-(2-Dimethylamino)ethyl)morpholine 0 4-Androstene-3,17-dione 1 4-Hydroxytamoxifen 1 4-Hydroxytoremifene 1 4-Iodotamoxifen 1 4-beta-Phorbol 12,13-dibutyrate 1 4-beta-Phorbol 13-acetate 0 4-beta-Phorbol 13-butyrate 0 5-(N,N-hexamethylene)amiloride 0 5-(N-Methyl-N-isobutyl)amiloride 0 5-N-acetyl-8-demethylardeemin 1 5-N-acetylardeemin 1 5-[N-Methyl-N-(tert-butyl)]-amiloride 0 6-Phenyl-2,4,7-pterid 0 7,8-Dihydroxychlorpromazine 0 7-Hydroxychlorpromazine 0 AF-1393 1 AG-1112 0 AG-213 0 AG-690 1 AHC-52 1 AHR 06601 1 AHR 16462 1 AHR-16303 1 AN-989 1 AY 9944 1 Acapriazine 0 Acebutolol 0 Acecainide 0 Acepromazine 1 Aceprometazine 1 Acetophenazine 1 Acridine 0 Acridone-4-carboxamide 22 1 Acridone-4-carboxamide 23 1 Acridone-4-carboxamide 24 1 Acridone-4-carboxamide 28 1 Acridone-4-carboxamide 29 1 Acridone-4-carboxamide 30 1 Acridone-4-carboxamide 31 1 Acridone-4-carboxamide 32 1 Acridone-4-carboxamide 36 1 Acridone-4-carboxamide 39 1 Acridone-4-carboxamide 43 1 Acridone-4-carboxamide 44 1 Acridone-4-carboxamide 47 1 Acridone-4-carboxamide 48 1 Acridone-4-carboxamide 49 1 Acridone-4-carboxamide 50 1 Acridone-4-carboxamide 51 1 Acridone-4-carboxamide 52 1 Acridone-4-carboxamide 53 1 Acridone-4-carboxamide 54 1 Acridone-4-carboxamide 55 1 Acridone-4-carboxamide 59 1 Acridone-4-carboxamide 60 1 Acridone-4-carboxamide 61 1 Acridone-4-carboxamide 64 1 Acridone-4-carboxamide 65 1 Acridone-4-carboxamide 66 1 Acridone-4-carboxamide 67 1 Acridone-4-carboxamide 68 1 Acridone-4-carboxamide 69 1 Acridone-4-carboxamide 70 1 Acridone-4-carboxamide 71 1 Acridone-4-carboxamide 72 1 Acridone-4-carboxamide 73 1 Acridone-4-carboxamide 74 1 Acridone-4-carboxamide 75 1 Acridone-4-carboxamide 76 1 Acridone-4-carboxamide 77 1 Acridone-4-carboxamide 78 1 Acridone-4-carboxamide 79 1 Acridone-4-carboxamide 80 1 Acridone-4-carboxamide 81 1 Acridone-4-carboxamide 82 1 Acridone-4-carboxamide 83 1 Acridone-4-carboxamide 85 1 Acrivastine 0 Actinomycin D 0 Adiphenine 0 Aldicarb 0 Aldoxycarb 0 Aldrich 21430-2 1 Almitrine 1 Alpertine 1 Alpha-Tocopherol 0 Alprenolol 1 Alverine Amantadine 0 Ambodryl 0 Amiloride 0 Aminocarb 0 Aminopentamide 0 Amiodarone 1 Amitriptyline 1 Amlodipine 1 Amodiaquin 0 Amotriphene 1 Amoxapine 1 Amoxecaine 0 Amperozide 1 Amphotericin B 0 Amprenavir 1 Androstenedione 1 Androsterone 1 Antazoline 0 Antenolol 0 Antipyrine 0 Apomorphine 0 Aprindine 1 Ascorbic acid 0 Asocainol 1 Astemizole 1 Atorvastatin (methyl ester) 1 Atorvastatin lactone 1 Atrazine 0 Atropine 0 Aureobasidin A (ABA) 1 Azaclorazine 1 Azaconazole 0 Azaperone 0 Azelastine 1 Azidopine 1 Azidoprocainamide methoiodide 0 Azipramine 1 B3-243 1 B669 1 B9109-012 1 BIBW 22 1 BW 1019W91 1 BW 1136U89 1 BW 1288U89 1 BW 1351W91 1 BW 1379W91 1 BW 565C81 1 Bamipine 0 Barnidipine 1 Befuraline 0 Benactyzine 0 Bencyclane 0 Benidipine 1 Benzathine 1 Benzmalecene 0 Benzofuran derivative 2a 0 Benzofuran derivative 2c 1 Benzofuran derivative 2d 1 Benzofuran derivative 2e 1 Benzofuran derivative 2f 1 Benzquinamide 0 Benztropine 1 Bepridil 1 Berberine 0 Bevantolol 1 Bifonazole 1 Biperiden 0 Biphenamine 0 Biricodar 1 Bisobrin 0 Bleomycin A2 0 Boldine 0 Boxidine 0 Bromocriptine 1 Brompheniramine 0 Bryostatin 0 Bucainide 1 Buclizine 1 Budipine Buflomedil 0 Bufuralol 1 Bunaftine 1 Buspirone 1 Butalamine 0 Butaperazine 1 Buterizine 1 Butethamate 0 CP-100356 1 CP-101556 1 CP-114416 1 CP-114769 1 CP-117227 1 CP-12379 1 CP-141938 1 CP-147478 1 CP-69042 1 Calcimycin 0 Calphostin C 1 Captodiame Carbamazepine 0 Carbaryl 0 Carbinoxamine 1 Carbiphene 1 Carnitine 0 Caroverine 1 Carphenazine 1 Carvedilol 1 Carvedilol metabolite M2 0 Carvedilol metabolite M4 0 Carvedilol metabolite M5 0 Catharanthine 1 Cefoperazone 0 Cefotetan 0 Ceftazidime 0 Celiprolol 0 Cepharanthine 1 Cephradine 0 Cetiedil 1 Cetrizine 0 Chelerythrine 0 Chlophedianol 0 Chloracyzine 1 Chlorbenzoxamine 1 Chlorcyclizine 0 Chlorogenic acid 0 Chloropyramine 0 Chloroquine 0 Chlorpheniramine 0 Chlorphenoxamine Chlorproethazine 1 Chlorpromazine 1 Chlorprothixene 1 Chlorzoxazone 0 Chromonar Cimetidine 0 Cinchonidine 1 Cinepaxadil 1 Cinepazet 0 Cinepazic acid 0 Cinepazide 0 Cinnarizine 1 Cinprazole 1 Cinpropazide 0 Cintriamide 0 Cinuperone 1 Ciprofloxacin 0 Citalopram 0 Citatepine 1 Citenamide 0 Clamoxyquin 0 Clanobutin 0 Clebopride 0 Clemastine 1 Clemizole 1 Cletoquine 0 Clobutinol 0 Clocinizine 1 Clomestrone 0 Clomiphene 0 Clomipramine 1 Clonidine 0 Clopenthixol 1 Cloperastine 1 Clopimozide 1 Clopipazan 1 Clothiapine 1 Clothixamide 1 Clotrimazole 1 Colchicine 0 Colforsin 1 Coralyne 0 Corticosterone 0 Cortisone 0 Corynanthine 1 Coumaphos 1 Cryptophycin 1 Cyclobenzaprine 1 Cyclofenazine 1 Cyclopeptolide(1) 0 Cyclopeptolide(11) 0 Cyclopeptolide(12a) 1 Cyclopeptolide(12b) 1 Cyclopeptolide(15a) 1 Cyclopeptolide(15b) 1 Cyclopeptolide(16a) 1 Cyclopeptolide(16c) 1 Cyclopeptolide(16h) 1 Cyclopeptolide(18) 1 Cyclopeptolide(19) 0 Cyclopeptolide(2a) 1 Cyclopeptolide(2c) 1 Cyclopeptolide(2f) 1 Cyclopeptolide(3a) 1 Cyclopeptolide(3c) 1 Cyclopeptolide(3f) 1 Cyclopeptolide(3g) 1 Cyclopeptolide(3h) 1 Cyclopeptolide(3i) 1 Cyclopeptolide(3j) 1 Cyclopeptolide(3l) 1 Cyclopeptolide(3n) 1 Cyclopeptolide(4) 1 Cyclopeptolide(7) 1 Cyclopeptolide(8) 1 Cyclopeptolide(9) 1 Cyclophenazine 1 Cyclosporin A 1 Cyclosporin C 1 Cyclosporin G 1 Cypermethrin 1 Cyproheptadine 1 Cytochalasin A 0 Cytochalasin C 0 Cytochalasin D 0 Cytochalasin E 1 Cytochalasin H 0 Cytochalasin J 0 D490 1 D525 1 D528 0 D557 1 D559 1 D595 1 D784 1 D894 1 DDE 0 DDT 0 DHP-014 1 DMDP 1 DPDPE 0 Dagapamil 1 Danitracen 0 Dapiprazole 0 Darodipine 1 Debrisoquin 0 Dehydroemetine 0 Delavirdine 1 Delfantrine 0 Deltorphin II 0 Denzimol 0 Deoxycorticosterone 1 Desethylamiodarone 1 Desipramine 1 Desmethoxyyangonin 1 Desmethylazelastine 1 Desmethylchlorpromazine 0 Desmethylcitalopram 0 Desmethylsertraline 1 Devapamil 1 Dexamethasone 0 Dexniguldipine 1 Dialifos 0 Dibenzylamine 0 Dibozan 0 Dibucaine 1 Dicapthon 1 Diclofensine 0 Didesmethylchlorpromzine 0 Diethylaniline 0 Diethylstilbestrol 1 Difloxacin 0 Difluanine 1 Digoxin 0 Dihydroergotamine 0 Dihydromethysticin 1 Dihydropyridine DP11 1 Dihydropyridine DP5 1 Dihydropyridine DP6 1 Dihydropyridine DP7 1 Dihydropyridine DP9 1 Dihydropyrroloquinoline series 14 0 Dihydropyrroloquinoline series 27 1 Diisopromine Dilazep 1 Diltiazem 1 Dimethindene 1 Diosmetin 0 Diosmin 0 Diphenamid 0 Diphenazoline 0 Diphenidol 1 Diphenylpyraline 1 Disopyramide 0 Dixyrazine 1 Dobutamine 0 Doconazole 1 Domperidone 0 Doxapram 1 Doxazosin Doxepine 1 Doxorubicin 0 Doxylamine 0 Drobuline 1 Drofenine 0 Droloxifen 0 Droprenilamine 1 Droproizine 0 Duoperone 1 EKI-785 1 Ebastine 1 Econazole 0 Efonidipine 1 Eletriptan 0 Eltoprazine 0 Emepronium 0 Emetine 0 Emopamil 1 Enciprazine 1 Endosulfan 1 Enilconazole 0 Enoxacin 0 Epinephrine 0 Eprazinone 1 Eprozinol 1 Equilenine 0 Equilin 0 Ergocristine 1 Ergocryptine 1 Ergonovine 0 Ergotamine 1 Erythromycin 1 Estradiol 0 Estriol 0 Estrone 0 Etafenone 1 Ethylbenztropine 1 Ethylbenzylaniline 0 Etifelmin 0 Etodroxizine Etolotifene 1 Etomidoline 1 Etoposide 0 Euphodendroidin A 1 Euphodendroidin B 1 Euphodendroidin C 1 Euphodendroidin D 1 Euphodendroidin E 1 Euphodendroidin G 1 Euphodendroidin H 1 Euphodendroidin I 1 Euprocin 1 Falipamil 0 Famciclovir 0 Farnesyl analog AFCA 1 Farnesyl analog AFCMA 1 Farnesyl analog AFCME 1 Febuverine 1 Felodipine 1 Fenbutrazate 1 Fendiline 1 Fenoctimine 0 Fenoterol 0 Fenoxedil 1 Fenpipramide 0 Fenpiverinium 0 Fenticonazole 1 Fenvalerate 0 Fexofenadine 0 Filipin 0 Fisetin 0 Flavonoid ID 13 1 Flavonoid ID 21 0 Flavonoid ID 22 0 Flavonoid ID 23 0 Flavonoid ID 24 0 Flavonoid ID 37 1 Flavonoid ID 38 0 Fleroxacin 0 Flesinoxan 0 Flezelastine 1 Flordipine 1 Fluanisone 1 Fluazifop-butyl 0 Fluconazole 0 Flumazenil 0 Flunarizine 1 Fluoxetine 1 Fluperamide 1 Fluperlapine 1 Fluphenazine 1 Flurazepam 1 Fluspirilene 1 Fluvoxamine 1 GF120918 1 GGCME 1 GW 420867 1 Gallopamil 1 Gamfexine 0 Geldanamycin 1 Geldanamycin 17-AAG 1 Gepirone 0 Ginsenoside Rg3 1 Ginsenoside Rh2 1 Glaucine 1 Gramine 0 Guanabenz 0 Guanfacine 0 H-7 0 H-89 1 HA-1004 0 HDL-2722 0 Halopemide 1 Haloperidol 1 Hepzidine 1 Hexadiline 0 Hexobendine 1 Hexoprenaline 0 Histapyrrodine 0 Hoechst 33342 0 Homochlorocyclizine 0 Homofenazine Homoveratrylamine 0 Hoquizil 0 Hydramethylnon 1 Hydrastine 0 Hydrocotarnine 0 Hydromorphone 0 Hydroxyzine 1 Hyperforin 0 Idarubicin 1 Imatinib 1 Imiclopazine 0 Imipramine 1 Imolamine 0 Imoxiterol 0 Indinavir 0 Indomethacin 0 Isoconazole
Load more

Recommended publications
  • Alzheimer's Disease, a Decade of Treatment: What Have We Learned?
    A Critical Look at Medication Dementia: Alzheimer’s Disease Management Issues in Alzheimer’s Disease R.Ron Finley, B.S. Pharm., R.Ph,CGP Lecturer (Emeritus) and Assistant Clinical Professor, UCSF School of Pharmacy Clinical Pharmacist, UCSF Memory and Aging Center- Alzheimer’s Research Center Educational Objectives Disclosures 1. Define the role for cholinesterase inhibitors in the management of Alzheimer’s disease, Lewy Body dementia, Frontal Temporal Lobe dementia. Pfizer Speakers Bureau 2. Name three common side effects of atypical antipsychotic Forest Speakers Bureau drugs. Novartis Speakers Bureau 3. Construct a pharmacological treatment plan for a 77-year-old Rx Consultant Associate Editor patient diagnosed with Alzheimer’s disease and hallucinations. WindChime Consultant 4. Describe the role for antipsychotic, antidepressant, mood HGA HealthCare Consultant stabilizers and benzodiazepines in the management of psychiatric behavior problems related to Alzheimer’s disease. Elder Care Specialist Consultant 5. Cite three potential drug or disease interactions with cholinesterase inhibitors. The Many Faces of Dementia Risk Factors Linked to AD Alzheimer’s Disease Over 65 years of age and increases Vascular: Multi-infarct with age FrontalTemporal Lobe dementia ( FTD) and female Pick’s disease Head injury Lewy Body Dementia Progressive Supranuclear Palsy Factors associated with DM, HTN, CVD Corticobasal Degeneration Genetic: family history, specific Primary Progressive Aphasia chromosome mutations Huntington’s disease
    [Show full text]
  • Meprobamate Art 107 AR
    30 March 2012 EMA/212617/2012 Assessment report for meprobamate-containing medicinal products for oral use Procedure number: EMEA/H/A-107/1316 Procedure under Article 107 of Directive 2001/83/EC, as amended Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Discussion on safety ............................................................................................. 4 2.2.1. Non-clinical data ................................................................................................ 4 2.2.2. Clinical safety .................................................................................................... 4 2.2.2.1. Clinical studies ..............................................................................................
    [Show full text]
  • Synthetic Drugs
    Comprehensive and Confident Identification of Narcotics, Steroids and Pharmaceuticals in Urine David E. Alonso1, Petra Gerhards2, Charles Lyle1 and Joe Binkley1 | 1LECO Corporation, St. Joseph, MI; 2LECO European LSCA Centre, Moenchengladbach, Germany Introduction Experimental Sample A (Traditional Drugs) Sample B (Synthetic Drugs) Monitoring of patients in hospitals and clinics has traditionally relied on Samples Representative Compounds Representative Compounds targeted methods of analysis. These screening methods are not Peak # Name Formula R.T. (s) Area Similarity Mass Delta (mDa) MA (ppm) 1 Creatinine ME C5H9N3O 210 1326229 800 -0.05 -0.43 • Obtained from a collaborating European hospital 3.5e6 3.0e6 Peak # Name Formula R.T. (s) Area Similarity 2 o-Ethynylaniline C8H7N 219 167436 893 0.07 0.63 1 Indole C8H7N 213 2744171 917 comprehensive and result in an incomplete picture of a patient’s 3 2-Methoxy-4-vinylphenol C H O 223 65764 805 0.11 0.73 52 patient monitoring samples 9 10 2 2 Creatinine ME C5H9N3O 216 613318 651 • 2.5e6 4 Nicotine C10H14N2 234 3249121 898 -0.21 -1.29 3 Pyridine, 2-(1-methyl-2-pyrrolidinyl)- C10H14N2 230 24869771 899 activities. Gas chromatography high resolution time-of-flight mass 3.0e6 5 Hordenin C10H15NO 274 949734 775 -0.14 -0.84 4 Parabanic acid, 1-methyl- C4H4N2O3 233 434278 764 Sample preparation 5 Cotinine C10H12N2O 336 27810908 918 • 6 Methylecgonine C10H17NO3 276 104640 835 -0.22 -1.1 spectrometry (GC-HRT) provides a fast and convenient method for 2.0e6 5 6 Caffeine C8H10N4O2 371 3753598 797 2.5e6 7 4-(3-Pyridyl-tetrahydrofuran-2-one C9H9NO2 313 93817 849 -0.11 -0.68 3,4 7 1-methyl-7H-xanthine C6H6N4O2 437 4868196 850 analysis of urine samples.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • Anti-Inflammatory Effects of Amantadine and Memantine
    Journal of Personalized Medicine Communication Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19? Félix Javier Jiménez-Jiménez 1,* , Hortensia Alonso-Navarro 1 , Elena García-Martín 2 and José A. G. Agúndez 2 1 Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, E-28500 Madrid, Spain; [email protected] 2 University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, E-10071 Cáceres, Spain; [email protected] (E.G.-M.); [email protected] (J.A.G.A.) * Correspondence: [email protected]; Tel.: +34-636968395 Received: 2 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Abstract: We have reviewed current data on the anti-inflammatory effects of amantadine and memantine in clinical and in vivo models of inflammation, and we propose that these effects have potential interest for the treatment of the SARS-CoV-2 infection (COVID-19 disease). To that end, we performed a literature search using the PubMed Database from 1966 up to October 31 2020, crossing the terms “amantadine” and “memantine” with “inflammation” and “anti-inflammatory”. Amantadine and/or memantine have shown anti-inflammatory effects in chronic hepatitis C, in neuroinflammation induced by sepsis and by lipopolysaccharides, experimental models of multiple sclerosis, spinal cord injury, and respiratory diseases. Since the inflammatory response is one of the main pathogenetic mechanisms in the progression of the SARS-CoV-2 infection, anti-inflammatory effects of amantadine and memantine could be hypothetically useful in the treatment of this condition. This potential utility deserves further research. Keywords: amantadine; memantine; anti-inflammatory effects; SARS-Cov-2; COVID-19; therapy 1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Analysis of Metals in Surface Water Samples
    ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Annex I Analysis of metals in surface water samples Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia October 2020 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Surface water samples Cd (ug/L) Pb (ug/L) Hg (ug/L) Ni (ug/L) As (ug/L) Cr (ug/L) Cu (ug/L) Zn (ug/L) Metals – limit values 0.15** 1.2** 0.07*** 4** 24* 9.0* 1.6* 9.6* Table 1: Results of analyses of Sampling point 1 filtered <LOQ <LOQ <LOQ <LOQ 3.38 <LOQ 1.15 4.0 metals in surface water samples. Sampling point 2 filtered 0.547 <LOQ <LOQ 1.845 <LOQ 0.666 1.94 26.5 The values represent dissolved Sampling point 3 filtered <LOQ <LOQ <LOQ <LOQ 1.99 <LOQ 0.89 4.1 concentrations (after filtration of Sampling point 4 filtered <LOQ <LOQ <LOQ 1.33 <LOQ <LOQ 4.21 9.2 the samples). Numbers Sampling point 5 filtered 2.66 <LOQ <LOQ <LOQ <LOQ 2.35 9.39 20.6 highlighted in orange colour Sampling point 6 filtered <LOQ <LOQ <LOQ <LOQ 2.62 <LOQ 4.95 6.9 indicate exceedance of the Sampling point 7 filtered 0.345 <LOQ <LOQ <LOQ <LOQ 0.777 6.06 38.4 toxicity threshold values. Sampling point 8 filtered <LOQ <LOQ <LOQ <LOQ 2.65 <LOQ 1.03 61.7 Sampling point 9 filtered 0.129 <LOQ <LOQ <LOQ 2.29 0.85 5.36 16.4 Sampling point 10 filtered <LOQ <LOQ <LOQ 1.772 <LOQ <LOQ <LOQ 7.9 Sampling point 11 filtered 0.292 <LOQ <LOQ <LOQ <LOQ 1.31 0.82 11.9 Sampling point 12 filtered 0.328 <LOQ <LOQ <LOQ <LOQ 3.89 1.34 2.6 Sampling point 13 filtered <LOQ
    [Show full text]
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Exploring Pharmacological Significance and Reaction Dynamics of Piperazinemoiety
    Exploring Pharmacological Significance and Reaction Dynamics of PiperazineMoiety. Rajashree A. Markandewar 1, S R Deshmukh 2 and M.A Baseer 3 1,2 Dept. of Chemistry, R. M. G.Mahavidyalaya, Saoli, Dist Chandrapur-441225 3Dept. of Chemistry, YeshwantMahavidyalaya, Nanded- 431602 Abstract: Piperazines and their analogs are amongst the most important backbones in today’s drug discovery industries. The purpose of this paper is to provide an overview of the pharmacological properties of piperazines and Reaction dynamics. The synthesis of of 4-(4- methyl piperazine-l-yl) benzaldehyde a variety of Nitrogen containing aldehyde is described with proper choice of base, solvent and temperature conditions. This work is underway to ameliorate difficulties which remain, especially in finding suitable reaction dynamics that efficiently increases the yield. The synthesized compounds were characterized by IR, 1HNMR and MS Spectroscopy. Keywords: Piperazines Nitrogen-containing-aldehyde, Reaction dynamics, N-arylation . Introduction: Synthetic chemistry provides corpucopia of heterocyclic systems. More than 90% of new drugs contain heterocycles and the interface between chemistry and biology. The modern day medicinal chemistry is based on heterocyclic molecules and we owe to them, due to their close association with numerous biological as well as pharmacological activities. Nitrogen containing heterocycles is subunit found in numerous natural products and in many biologically active pharmaceuticals [1]. An important aspect of medicinal chemistry is to establish as relationship between chemical structure and pharmacological activity. Piperazine is a sex membered ring structure containing twoopposing nitrogen atoms. Nitrogen containing compounds is used as structural components of pharmaceuticals and agrochemicals due to their high biological activities. There are many nitrogen containing chemicals, ranging from simple structural compounds as pyridine to complicated compounds as pharmaceuticals ingredients and their number is growing rapidly year by year [2].
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]